ORIGINAL ARTICLE

IFT81, encoding an IFT-B core protein, as a very rare cause of a ciliopathy phenotype

Isabelle Perrault,1,2 Jan Halbritter,3,4 Jonathan D Porath,4 Xavier Gérard,1,2 Daniela A Braun,4 Heon Yung Gee,4 Hanan M Fathy,5 Sophie Saunier,2,6 Valérie Cormier-Daire,2,7 Sophie Thomas,2,8 Tania Attié-Bitach,2,8 Nathalie Boddart,9 Michael Taschner,10 Markus Schueler,4 Esben Lorentzen,10 Richard P Lifton,11 Jennifer A Lawson,4 Meriem Garfa-Traore,2,12 Edgar A Otto,13 Philippe Bastin,14 Catherine Caillaud,15 Josseline Kaplan,1,2 Jean-Michel Rozet,1,2 Friedhelm Hildebrandt4,16

ABSTRACT

Background Bidirectional intraflagellar transport (IFT) consists of two major protein complexes, IFT-A and IFT-B. In contrast to the IFT-B complex, all components of IFT-A have recently been linked to human ciliopathies when defective. We therefore hypothesised that mutations in additional IFT-B encoding genes can be found in patients with multisystemic ciliopathies.

Methods We screened 1628 individuals with renal-ocular ciliopathies by targeted next-generation sequencing of ciliary candidate genes, including all IFT-B encoding genes.

Results Consequently, we identified a homozygous mutation in IFT81 affecting an obligatory donor splice site in an individual with nephropathies and polydactyly. Further, we detected a loss-of-stop mutation with extension of the deduced protein by 10 amino acids in an individual with nephronophthisis and polydactyly. Further, we detected a loss-of-stop mutation with extension of the deduced protein by 10 amino acids in an individual with nephropathies and polydactyly. Further, we detected a loss-of-stop mutation with extension of the deduced protein by 10 amino acids in an individual with nephropathies and polydactyly. Further, we detected a loss-of-stop mutation with extension of the deduced protein by 10 amino acids in an individual with nephropathies and polydactyly. Further, we detected a loss-of-stop mutation with extension of the deduced protein by 10 amino acids in an individual with nephropathies and polydactyly.

Conclusions This work describes identification of mutations of IFT81 in individuals with symptoms consistent with the clinical spectrum of ciliopathies. It might represent the rare case of a core IFT-B complex protein found associated with human disease. Our data further suggest that defects in the IFT-B core are an exceedingly rare finding, probably due to its indispensable role for ciliary assembly in development.

INTRODUCTION

Intraflagellar transport (IFT) is an ancient kinesin and dynein-mediated bidirectional trafficking system essential for cilium assembly and maintenance. It has been conserved from green algae (Chlamydomonas reinhardtii) to humans. There are two major IFT subcomplexes within the cilium, A and B. While the IFT-A complex is primarily involved in retrograde transport from tip to base, the IFT-B complex is mainly part of the anterograde transport from base to tip.1 Very recently, all six components of the IFT-A complex have been found defective in individuals with a distinct form of nephropathies-related ciliopathies (NPHP-RC), namely skeletal ciliopathies.2 Skeletal ciliopathies primarily present with a bone-related phenotype such as shortened long bones and ribs (eg, in short rib-polydactyly syndromes, MIM 263510; Jeune asphyxiating thoracic dystrophy, MIM 208500), phalangeal cone-shaped epiphyses (eg, in Mainzer-Saldino syndrome, MIM 266920) or dolichocephaly and hypooradontia (eg, in Sensenbrenner syndrome/cranioectodermal dysplasia; MIM 218330).2

With regards to the IFT-B complex, defects in only 4 out of 14 members have been associated with human disease to date. Those four components are IFT80, IFT88, IFT172 and very recently IFT27.3-6 Defects in any of them result in short rib-polydactyly syndromes, Jeune asphyxiating thoracic dystrophy, Mainzer-Saldino syndrome, or a reno-oculo-hepatic ciliopathy with polydactyly (Bardet-Biedl syndrome, MIM 209900), in the case of IFT27. One of the possible reasons why the IFT-B complex has not been as commonly associated with human ciliopathy phenotypes as the IFT-A complex, is its crucial role in cilogenesis, as evidenced by embryonic lethality in many established mutant mouse models.7,8 The IFT-B complex consists of a nine-subunit salt-stable core (IFT80, IFT81, IFT74, IFT70, IFT52, IFT46, IFT27, IFT25, IFT22/RABL5) and five peripheral components (IFT172, IFT80, IFT57, IFT54/ TRAF3IP1, IFT20). Peripheral components are characterised by dissociation from the core at NaCl concentrations above 300 mM.9 Although first described in Chlamydomonas, a very similar subcomplex composition was also characterised in mice.10 Interestingly, the previously identified IFT-B complex components associated with ciliopathies in humans, IFT80 (MIM 611177) and IFT172 (MIM 607386), encode for non-core units, whereas defects of core members have only been found in a single case with an evolutionary conserved missense mutation in IFT88 and in a single case in IFT27 encoding a small GTPase.5,6

For numbered affiliations see end of article.

Correspondence to Professor Friedhelm Hildebrandt, Professor of Pediatrics, Harvard Medical School, Director, Division of Nephrology, Investigator, Howard Hughes Medical Institute, Boston Children’s Hospital, 300 Longwood Avenue, Boston, MA 02115, USA; friedhelm.hildebrandt@childrens.harvard.edu or Dr Jean-Michel Rozet, Director of Research, Head, Laboratory of Genetics in Ophthalmology, INSERM UMR1163, Imagine Institute of Genetic Diseases, 24 boulevard du Montparnasse, 75015 Paris, France; Jean-michel.rozet@inserm.fr

These authors contributed equally, IP and JH share first authorship.

Received 27 October 2014 Revised 7 June 2015 Accepted 15 June 2015 Published Online First 14 August 2015

therefore investigated in a large cohort of 1628 individuals with NPHP-RC, retinal ciliopathies, or multisystemic ciliopathies whether recessive mutations in genes encoding for IFT-B core components could be detected.

METHODS

Patients
Written informed consent was obtained from 1628 individuals with reno-ocular ciliopathies (1056 patients at University of Michigan/Boston Children’s Hospital with NPHP-RC + 572 patients with either NPHP-RC (n=202), skeletal ciliopathies (n=158), embryonically lethal ciliopathies (n=136), early onset retinal dystrophies without cerebro-skeleto-renal symptoms (n=69), and oculo-cerebro ciliopathies (n=7) at INSERM UMR1163, Imagine Institute of genetic diseases, Paris). The diagnosis of early onset severe retinal dystrophy and NPHP-RC was based on published clinical criteria.11 12

Targeted and whole exome resequencing
Genomic DNA was extracted from peripheral blood samples by standard salt precipitation methods.
Targeted amplification in the Boston cohort was performed by multiplexed PCR using Fluidigm Access-Array technology followed by barcoding and next-generation resequencing (NGS) on an Illumina MiSeq platform, as previously established by our group.13 14 Sanger DNA sequencing was further conducted for single mutation confirmation. All coding exons and adjacent splice sites of the following 14 IFT-B encoding genes were screened: IFT172/SLB, IFT88, IFT81/CDV1, IFT80, IFT54/ TRAF3IP1, IFT22/RABL5, IFT52, IFT46, IFT57/HIPPI, IFT74/ CCDC2, HSPB11/IFT25, IFT20, IFT27, TTC30B/IFT70 (see online supplementary table S1). In the Paris cohort, ‘ciliome resequencing’ was carried out by a 5.3 Mb customised Agilent SureSelect Target Enrichment Library capturing 32 146 exons of 1666 genes selected from CiliaProteome, Ciliadb and data from the literature.15 In individual A3286-21, we subsequently combined homozygosity mapping and whole exome resequencing (WER) for complete mutation analysis. For genome-wide homozygosity mapping, the ‘Human Mapping 250 k StyI’ array was used. Genomic DNA samples were hybridised, and scanned using the manufacturer’s standard protocol at the University of Michigan core facility. Non-parametrical logarithm of odds scores were calculated using a modified version of the programme GENEHUNTER V2.1.16 through stepwise use of a sliding window with sets of 110 SNPs using the programme ALLEGRO.17 Genetic regions of homozygosity by descent (‘homozygosity peaks’) were plotted across the genome as candidate regions for recessive genes, as described in Gee et al.18 Disease allele frequency was set at 0.0001, and Caucasian marker allele frequencies were used. WER in A3286-21 and variant burden analysis was performed as described previously.19 In brief, genomic DNA was isolated from blood lymphocytes and subjected to exome capture using Agilent SureSelect human exome capture arrays (Life technologies) followed by NGS on the Illumina sequencing platform as previously described. Illumina’s processing software ELAND (CASAVA V1.8.2) was used to map reads to the human reference genome (build 19), and SAMTools37 was used to call single nucleotide variants and insertion/deletion at targeted bases. Variants with minor allele frequencies <1% in the Yale (1972 European subjects), National Heart Lung and Blood Institute Grant Opportunity (NHLBI) GO Exome Sequencing Project (4300 European and 2202 African American subjects; last accessed November 2012), dbSNP (V.135) or 1000 Genomes (1094 subjects of various ethnicities; May 2011 data release) databases were selected and annotated for impact on the encoded protein and for conservation of the reference base and amino acid among orthologs across phylogeny. The whole exome of NCK033 was captured using the SureSelect Human All Exon Kits V3 (Agilent, France). Ciliome and exome were sequenced (2×75 bp) using the Illumina HiSeq2000 system at the Genomic Core Facility of the Imagine Institute (Paris, France). Sequences were aligned to the human genome reference sequence (hg19 assembly), and SNPs were called based on allele calls and read depth using the CASAVA pipeline (Consensus Assessment of Sequence and Variation 1.8, Illumina). Genetic variation annotation was performed by an inhouse pipeline. Only the variants whose positions were covered ≥10× were further considered. Applied exclusion criteria further comprised (1) synonymous or intronic variants other than those affecting the consensus splice sites; (2) variants seen in more than 1% of an inhouse exome data set (n=5571) from unrelated projects; and (3) variants with a minor allele frequency greater than 0.5% in either the 1000 genomes or the exome variant server (EVS) data sets. We hypothesised an autosomal recessive mode of inheritance and focused our attention on homozygous variants.

Reverse transcriptase PCR
Total RNA was extracted using the RNeasy Mini Kit (Qiagen, France) according to the manufacturer’s protocol. All samples were DNase treated by the RNase-free DNase set (Qiagen). Concentration and purity of total RNA was assessed using the Nanodrop-8000 spectrophotometer (Thermo Fisher Scientific, France). First-stranded cDNA synthesis was performed from 500 ng of total RNA extracted using Verso cDNA kit (Thermo Fisher Scientific) with random hexamers:anchored oligo (dT) primers at a 3:1 (vol:vol) ratio according to the manufacturer’s instructions. A non-reverse transcriptase (RT) reaction (without enzyme) for one sample was prepared to serve as control in RT-qPCR experiments.

Quantitative real-time RT-PCR
Patient (n=1) and control (n=3) fibroblasts were serum-starved for 48 h, and either exposed to a smoothened agonist (SAG, 100 nM) or negative control for 24 h. RNA was extracted separately for each condition and converted into cDNA. cDNAs were amplified as 161, 156, 103 and 140 bp fragments using specific primers designed from the GL11NM_005269.2, GL12NM_005270.4, SMONNM_005631.4 and PTCH1NM_000264.3 sequences, respectively (see online supplementary table S2). A 99 bp fragment of the human albumin gene (ALB, NM_000477) was used to control the non-contamination of cDNAs by genomic DNA. TBE B2M, GUSB, HPRT1, RPLP0 and ALB primers have been previously reported.20 cDNAs (5 μL of a 1:25 dilution in nuclease-free water) were subjected to real-time PCR amplification in a buffer (20 μL) containing SYBR® Green Master mix (Applied Biosystems) and 300 nmol/L of forward and reverse primers, on a mastercycler replex2 (Eppendorf). Data were analysed using the realplex software (Eppendorf). For each cDNA sample, the mean of quantification cycle (Cq) values was calculated from triplicates (SD<0.5 Cq). GLI1, GLI2, SMO and PTCH1 expression levels were normalised to the ‘normalisation factor’ obtained from the geNorm software for Microsoft Excel21 which uses the most stable reference genes and amplification efficiency estimates calculated for each primer pair using fourfold serial dilution curves (1:5, 1:25, 1:125, 1:625). Absence of amplification when using mRNA (non-RT) and water (W) as templates, and non-contamination of cDNAs
RESULTS
Phenotypes and genotypes
To identify disease-causing mutations, we independently applied different targeted candidate gene amplification methods with consecutive NGS to a two-centre cohort of 1628 (1056 + 572) individuals with ocular, neurological, skeletal and/or renal symptoms consistent with the diagnosis of ciliopathy. We first conducted a candidate gene screening of all 14 genes encoding IFT-B complex proteins (see online supplementary table S1) in 1056 individuals with NPHP-RC. In a 3-year-old girl of consanguineous Egyptian descent (A3286-21), who clinically presented with polydactyly, intellectual disability and NPHI, we detected a homozygous mutation affecting an obligatory donor splice site in IFT81 (intragenic transport 81 homologue Chlamydomonas; RefSeq accession number: NM_014055.3, MIM 605489) (c.1188 +1G>A) (table 1 and figure 1A–D). This variant was absent from all publicly available SNP databases and is predicted to be pathogenic by inframe skipping of exon 11 (~100% predicted change by MaxEnt/NNPSP/LICE/HSF). Familial segregation analysis was consistent with biallelicism (table 1). At birth the affected individual displayed postaxial polydactyly of the feet (figure 1Aa). At age of 1.5 years, bilateral hyperechogenic kidneys with loss of corticomedullary differentiation and small medullary cysts were detected by renal ultrasound (figure 1Ab). Kidney function, however, as measured by serum creatinine, was still preserved at the age of 5 years. Intellectual disability was moderate and comprised delayed speech and an IQ of 70 (~2 SDs below the mean). Cerebral MRI was not available to assess the presence of correlating morphological brain abnormalities. Funduscopic eye examination revealed normal retinal morphology at an age of 5 years, but electroretinographic (ERG) recordings were not performed.

Beyond family A3286, no further biallelic variants were considered ‘disease-causing’ in the remaining cohort of 1056 patients. Although mutations in genes known to be associated with NPHP once mutated (NPHP1-NPHP13) had been previously excluded, we further assessed A3286-21 for competing deleterious variants by combining WER with homozygosity mapping. In concordance with our previous finding, the IFT81-splice site variant (c.1188+1G>A) was ranked the most likely pathogenic allele, residing within a stretch of homozygosity on chromosome 12q (non-parametrical LOD score >2) (see online supplementary figure S1).

Second, we performed targeted resequencing of 1666 ciliary genes (‘ciliome resequencing’) in another 572 individuals with NPHP-RC, retinal or multisystemic ciliopathies. As a result, in an individual with retinal dystrophy and intellectual disability (NCK033), we found a homozygous deletion of five nucleotides in IFT81 resulting in a loss-of-stop codon and extension of the predicted protein by 10 amino acids (c.2015_2019del (p.Asp672Alafs*15)). For complete mutation analysis, consecutive WER was performed in NCK033. Thereby, nine additional rare homozygote variants were identified (see online supplementary figure S1), including a missense change (c.733G>A (p.Gly245Arg)) in the gene PPT1 encoding the palmitoyl-protein thioesterase (NM_000310.3; MIM600722). Familial segregation analysis demonstrated biallelism of the IFT81 and PPT1 changes (figure 1D and table 1). The PPT1 enzyme activity in the blood of the affected individual was strikingly decreased (5% of residual activity) confirming the clinical diagnosis of neuronal ceroid lipofuscinosis-1 (MIM265730). None of the patients’ two brothers inherited both IFT81 mutant alleles but one of them (NCK033, 23) inherited both PPT1 mutant alleles (figure 1D). The affected individual (NCK033) is
the first of three children of first-cousin Algerian parents (table 1 and figure 1A–D). He was born at term after unremarkable pregnancy and delivery. At an age of 4 years, the affected individual presented with visual loss, speech delay, mild intellectual disability and balance problems despite a reportedly normal cerebral MRI. Ophthalmological examination at the age of 7 years showed abnormal ocular movements, hemeralopia and poor vision. Retinography further revealed a degenerative aspect at the fundus (figure 1Ac), and ERG showed severely altered photopic and scotopic traces (see online supplementary figure S2), supporting early onset rod-cone dystrophy. Update of ophthalmological data at the age of 11 years revealed complete blindness with no residual light perception. Detailed neurological examination at age 9.5 years demonstrated an extrapyramidal and pyramidal syndrome with deep tendon and bilateral Babinski reflex. He also exhibited stereotypes, poor speech and echolalia. Repeated cerebral MRI showed diffuse cerebellar atrophy without molar tooth sign. In addition, axial echolalia. Repeated cerebral MRI showed diffuse cerebellar atrophy without molar tooth sign. In addition, axial

Table 1  Mutations of IFT81 and PPT1 in two families with a ciliopathy phenotype

<table>
<thead>
<tr>
<th>Family-individual/age</th>
<th>Gene</th>
<th>Nucleotide alteration</th>
<th>Deduced protein change</th>
<th>Exon/intron (zygoty)</th>
<th>Parental consanguinity</th>
<th>Renal disease (age of onset)</th>
<th>Eye disease (age of onset)</th>
<th>Additional clinical features</th>
</tr>
</thead>
<tbody>
<tr>
<td>A3286-21/5 year</td>
<td>IFT81</td>
<td>c.1188+1G&gt;A</td>
<td>5’ splice site</td>
<td>11 (Hom)</td>
<td>m: het/ p: ND</td>
<td>Yes</td>
<td>NPHP (1.5 year)</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>PPT1</td>
<td>c.733G&gt;A</td>
<td>Gly245Arg</td>
<td>8 (Hom)</td>
<td>m: het/ p: het</td>
<td>Yes</td>
<td>Polyuria/ Polydipsia</td>
<td>RD (4 year)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Family-individual/age</th>
<th>Gene</th>
<th>Nucleotide alteration</th>
<th>Deduced protein change</th>
<th>Exon/intron (zygoty)</th>
<th>Parental consanguinity</th>
<th>Renal disease (age of onset)</th>
<th>Eye disease (age of onset)</th>
<th>Additional clinical features</th>
</tr>
</thead>
<tbody>
<tr>
<td>A3286-21/5 year</td>
<td>IFT81</td>
<td>c.1188+1G&gt;A</td>
<td>5’ splice site</td>
<td>11 (Hom)</td>
<td>m: het/ p: ND</td>
<td>Yes</td>
<td>NPHP (1.5 year)</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>PPT1</td>
<td>c.733G&gt;A</td>
<td>Gly245Arg</td>
<td>8 (Hom)</td>
<td>m: het/ p: het</td>
<td>Yes</td>
<td>Polyuria/ Polydipsia</td>
<td>RD (4 year)</td>
</tr>
</tbody>
</table>

†COSM mutations are numbered according to human cDNA reference sequence NM_014055.3, isoform 1 (IFT81) and NM_000310.3, isoform 1 (PPT1), where +1 corresponds to the A of ATG start translation codon.

**Functional allele testing—decreased ciliation though unchanged ciliary localisation of IFT81**

To assess whether IFT81 mutant alleles affect cilia abundance, morphology or the subcellular localisation of IFT81, we performed immunofluorescence microscopy in primary skin fibroblasts of individual NCK033 and 4 healthy controls upon 48 h of serum starvation. The abundance of ciliated fibroblasts was significantly reduced in cells from the affected individual compared with controls (mean mutant cells vs mean control cells: 69.9% vs 83.9%, p=0.000026; mean control cells in the 83.6%±3.6% control range), indicating that the p.Asp672Alafs*15-protein variant causes defects in ciliogenesis and/or cilia maintenance (figure 2A, B). Overall, ciliary length of mutant cells appeared smaller than that of controls further supporting this hypothesis (figure 2C).

In ciliated fibroblasts from the affected individual (NCK033), however, IFT81 showed no difference compared with controls in terms of protein abundance as determined by western blot analysis (see online supplementary figure S3) as well as ciliary localisation (same predominant localisation to the tip and base at a distance from the centriole) and staining intensity as determined by immunocytochemistry analysis (figure 3A). To further address the question, whether the extended IFT81 protein would lead to impaired ciliary trafficking of other IFT-B core components, we stained for the IFT81-interactors IFT25 and RABL5/IFT22. Signals of IFT25 and RABL5/IFT22 were not decreased in the mutant fibroblasts (see figure 3B and online supplementary figure S4C). Likewise, staining for IFT88 and IFT46 which form a ternary subcomplex with IFT52 was similar in the control and the fibroblasts from the affected individual (see online supplementary figure S4A, B).

**Functional allele testing—GLI2 expression and localisation**

The role of primary cilia and IFT in sonic hedgehog (Shh) signalling is well established. To evaluate the impact of human IFT81 mutations on Shh signalling, we performed quantitative real-time PCR with primers specific to GLI1 (MIM 165220), GLI2 (MIM 165230), PTHC1 (MIM 601309) and SMO (MIM 601500). Interestingly, mRNA expression of the Shh-effector GLI2, but none of the other pathway components was significantly increased in the IFT81 mutant cell line (c.2015_2019del) compared with three different controls, when stimulated with a smoothened agonist for 24 h (SAG, 100 nM) (figure 4). We subsequently analysed the endogenous subcellular localisation of these Shh pathway components. By immunostaining, however, no major differences in ciliary localisation of SMO, GLI1 and GLI2 were detected before and after SAG stimulation in control and patient fibroblasts (see online supplementary figure S5).
Here, we report the identification of human mutations of IFT81 in two unrelated individuals with multisystemic symptoms consistent with ciliopathy phenotypes. Unlike many other IFT encoding genes, no mouse model has been reported for Ift81. However, an ift81 zebrafish mutant (hi409/larry) was first identified in a genetic screen for fish with cystic kidney disease.28 Somite-stage gene expression showed enrichment along classically ciliated organs; notochord, otic vesicle, pronephric duct, and around the cerebral ventricles, pointing towards an essential role of IFT81 in embryonic development of kidneys and brain.28 This is consistent with the view that IFT81 mutations can cause a ciliopathy in humans.

Mechanistically, our findings indicate altered Shh-signalling for at least one of our alleles (c.2015_2019del) (figure 4). The importance of GLI2 and the hedgehog pathway for limb
development in mammals is well established as postaxial polydactyly is a common feature in individuals with IFT mutations and suggests an exceedingly rare cause of a ciliopathy.

Cilia of mutant mice and human fetal samples have revealed a pivotal role of hedgehog signalling for the proliferation of granule cell progenitors. In addition, a direct correlation between Shh-signalling disruption, defective granule cell progenitor proliferation, and cerebellar hypo/aplasia in individuals with Joubert and Meckel syndrome has been described. While the cerebellar involvement is consistent with the cilia defect, the major signal enhancements in the periventricular and subcortical white matter (figure 1Ad-f) is not usually seen in patients with ciliopathies. From this point of view, it is important to stress that in addition to defective ciliogenesis, the activity of the PPT1 enzyme in the blood of NCK033 was dramatically low. PPT1 enzyme deficiencies are known to cause neuronal ceroid lipofuscinosis-1 (MIM 265730). This fatal neurological condition includes early onset severe retinal dystrophy and marked brain lesions. Importantly, segregation analysis of IFT81 and PPT1 variants showed that the younger of the two brothers is homozygous for PPT1 but heterozygous for the IFT81 mutation (figure 1D). While the index patient, NCK033, manifested at 4 years with visual loss, speech delay and ataxia, his 4-year-old brother currently has no overt retinal or neurological problems. In the absence of ERG and brain MRI from NCK033’s non-affected brother, a clinical follow-up will help to clearly discern the respective roles of PPT1 and IFT81 defects in the disease expression.

Considering kidney involvement, only the younger of the two individuals (A3286-21) had structural lesions, albeit with preserved renal function. However, the age of onset of renal manifestation has been shown to vary considerably between and within genetic subtypes of renal ciliopathies. Thus, it is difficult to anticipate whether the second individual (NCK033), age 10 years, is at risk for developing renal failure or whether the mutation extending the C-terminus of IFT81 does not affect kidney function. Recently he manifested symptoms of night enuresis, polyuria and polydipsia which might either be due to the neurological dysfunction or constitute first signs of a structural kidney disease. Similarly, retinal dystrophy in individual NCK033 only manifested at age 4 years, thus leaving it open whether the younger individual (A3286-21) may develop retinal dystrophy later in life. In addition, retinal involvement in individuals with other IFT mutations was also shown to be quite variable and is difficult to diagnose at an early stage without available ERG recordings, such as in A3286-21.

In summary, we here identify mutations in IFT81 and suggest that they represent an exceedingly rare cause of a ciliopathy phenotype in humans. The relatively mild clinical presentation...
together with insights from functional analysis indicates that both alleles constitute hypomorphs. IFT81 contains coiled-coil domains mediating its interaction with IFT74, and an N-terminal NN-CH domain, which is part of a tubulin-binding module. We suspect that neither of the detected human mutations would disrupt the IFT81-IFT74 complex. The interaction with IFT22/RABL5, however, was mapped to the linker region of IFT81 that localises just the C-terminal of the region encoded by exon 11 that is presumably skipped in A3286-21 (figure 1C, D). This may result in alteration or even abrogation of physical interaction between IFT22/RABL5 and IFT81. Extension of IFT81 by 10 amino acids (NCK033) does not lead to mislocalisation of IFT81 within the cilium, but to reduced ciliation, and alteration of Shh-signalling (figure 4), thereby possibly explaining some of the brain malformation. In contrast to other IFT-related phenotypes, major skeletal abnormalities were absent in the two individuals with IFT81 mutations. The low number of identified individuals and the additional PPT1 mutation in one of them, however, makes it difficult to draw genotype-phenotype correlations. As IFT81 represents the hub of the IFT-B core, more severe IFT81 defects may only be found in disease phenotypes that are incompatible with life.

Author affiliations
1Laboratory of Genetics in Ophthalmology, INSERM UMR 1163, Paris, France
2Paris Descartes—Sorbonne Paris Cité University, Imagine Institute, Paris, France
3Division of Endocrinology and Nephrology, Department of Internal Medicine, University Clinic Leipzig, Leipzig, Germany
4Division of Nephrology, Department of Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
5Pediatric Nephrology Unit, University of Alexandria, Alexandria, Egypt
6INSERM UMR 1163, Molecular bases of hereditary kidney diseases, Nephronophthisis and Hypodysplasia, Paris, France
7INSERM UMR 1163, Molecular and Physiopathological bases of osteochondrodysplasia, Paris, France
8INSERM UMR 1163, Embryology and genetics of human malformation, Paris, France
9Department of Pediatric Radiology, Hôpital Necker-Enfants Malades, APHP, Descartes University, Paris, France

Figure 4 Sonic hedgehog activity in IFT81 mutant fibroblasts (NCK033, p.Asp672Alafs*15) compared with three independent human control fibroblasts. All fibroblasts were serum-starved and maintained in culture without stimulation (−) or exposed to (+) a smoothened agonist (SAG). Relative expression levels of SMO, GLI1, GLI2 and PTCH1 mRNAs were determined by quantitative real-time PCR. Error bars represent the SEM derived from three independent experiments, each using triplicates. p Values were calculated applying unpaired Student’s t test (**p=0.015).

Figure 3 IFT81 localises to primary cilia with enrichment at base and tip. Immunofluorescence staining was performed in cultured human fibroblasts from healthy controls and affected individual NCK033 with the homozygous frameshift mutation (p.Asp672Alafs*15). (A) Note that cilia localisation of IFT81 to primary cilia did not show significant difference between control and mutant fibroblasts. (B) Ciliary signal of IFT25 did not show a significant difference between control and mutant fibroblasts. Scale bars represent 5 μm. IFT, intraflagellar transport.
This is an Open Access article distributed in accordance with the data, especially raw data, from the study. Provenance and peer review: Not commissioned; externally peer reviewed.

Children Institutional Review Boards at the University of Michigan/Boston Children’s Hospital; the Fondation de France; and the Imagine Institute, the ‘Association Rénaissance France’ and PHRC GENPHENACL to JMR and JK. FH is an Investigator of the Howard Hughes Medical Institute (HHMI) and a Warren E. Grupe Professor. The authors declare that they have no competing financial interests.

Competing interests: None declared.

Patient consent: Obtained.

Ethics approval: Institutional Review Boards at the University of Michigan/Boston Children’s Hospital and the Comité de Protection des Personnes ‘Ile-de-France’.

Provenance and peer review: Not commissioned; externally peer reviewed.

Data sharing statement: The authors are willing to share additional unpublished data, especially raw data, from the study.

Open access: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

REFERENCES
35 Conrales JD, Blaess S, Mahoney EM, Joyner AL. The level of sonic hedgehog signaling regulates the complexity of cerebellar foliation. Development 2006;133:1811–21.
**Fig. S1:** Homozygosity mapping of A3286-21 and final WER-variant table for A3286-21 and NCK033. (A) nonparametric LOD (NPL) scores from whole-genome mapping are plotted across the human genome. The x-axis shows Affymetrix 250K Sty array SNP positions on human chromosomes concatenated from pter to qter. Genetic distance is given in cM. Thirteen maximum NPL peaks (red circles) indicate candidate regions of homozygosity by descent. Note that the locus of \textit{IFT81} residues within one of the homozygous regions on chromosome 12 (black arrow). (B) Final remaining variants after filtering process. IFT81 variants are highlighted in yellow to indicate ranking as most likely disease causing. WDR35-missense variant in A3286-21 is highlighted in grey to indicate that nucleotide T is present in several closely related mammals (squirrel monkey, marmoset, dog, elephant) pointing towards a benign polymorphism. In NCK033, in addition to the change in \textit{IFT81}, the \textit{PPT1}-variant is most likely disease causing, as defects in the encoding enzyme are known to be associated with neuronal ceroid lipofuscinosis (CLN1).

**Mm - Mus musculus, Gg - Gallus gallus, Xt - Xenopus tropicalis, Dr - Danio rerio, Ci - Ciona intestinalis, Ce - Caenorhabditis elegans, Dm - Drosophila melanogaster , DC - Disease causing, Tol – Tolerated, n/a – not annotated, Poly 2, Polyphen2-Humvar; Mut Taster, Mutation Taster; EVS, Exome variant server.**

---

**A**

![Homozygosity mapping of A3286-21](image)

**B**

<table>
<thead>
<tr>
<th>Individual</th>
<th>Gene</th>
<th>hg19 pos.</th>
<th>Accession #</th>
<th>NT change &gt;</th>
<th>AA change p.</th>
<th>Amino acid conservation</th>
<th>Poly 2</th>
<th>Mut Taster</th>
<th>SIFT</th>
<th>1000 genomes</th>
<th>EVS</th>
</tr>
</thead>
<tbody>
<tr>
<td>A3286-21</td>
<td>\textit{IFT81} chr:11:10600087</td>
<td>NM_014055.3</td>
<td>G&gt;A</td>
<td>5' splice site</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>\textit{GDAP2} chr:11:120420467</td>
<td>NM_017666</td>
<td>C&gt;T</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>\textit{WDR35} chr:2:20137642</td>
<td>NM_001009657</td>
<td>C&gt;T</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>\textit{ROM} chr:2:21565149</td>
<td>NM_000379</td>
<td>C&gt;T</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>\textit{LAMC3} chr:13:33969885</td>
<td>NM_006019</td>
<td>G&gt;A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>\textit{OAS2} chr:12:11348219</td>
<td>NM_016817</td>
<td>C&gt;T</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCK033</td>
<td>\textit{IFT81} chr:11:10656015</td>
<td>NM_014055.3</td>
<td>delACCGG</td>
<td>D672Afs*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>\textit{PPT1} chr:11:40542579</td>
<td>NM_006019</td>
<td>G&gt;A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>\textit{MUTYH} chr:11:453781</td>
<td>NM_006019</td>
<td>C&gt;T</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>\textit{SEPT6} chr:11:48771080</td>
<td>NM_014979.3</td>
<td>A&gt;G</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>\textit{CC154} chr:11:14938480</td>
<td>NM_01149980</td>
<td>C&gt;T</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>\textit{NUAK1} chr:12:10644817</td>
<td>NM_014840.2</td>
<td>C&gt;T</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>\textit{OTU7A} chr:15:31776211</td>
<td>NM_139001.1</td>
<td>C&gt;T</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure S2. Patient NCK033 scotopic and photopic ERG traces. The morphology and culminating time of rod and cone responses are normal but the maximum response amplitudes are strikingly reduced. These traces are consistent with the diagnostic of rod-cone dystrophy. RE: right eye; LE: Left eye.
Figure S3. AB-specificity of IFT81 and protein expression in mutant fibroblasts.  
(A) Overexpression of either Mock or N-terminally His/Flag tagged IFT81. Note that the N-terminal tags add 18 kDa for an expected size of 99 kDa. Overexpressed IFT81 is significantly stronger than endogenously expressed detected by the anti-IFT81 Proteintech antibody used for IF.  
(B) Overexpression of either Mock or N-terminally His/Flag tagged IFT81. Note that the N-terminal tags add 18 kDa for an expected size of 99 kDa. Overexpressed IFT81 is significantly stronger than endogenously expressed (Atlas Antibodies: HPA019087).  
(C) IFT81 is specifically detected using anti-IFT81 (Atlas Antibodies: HPA019087).

HEK293 cells transfected with Mock or N-terminally His/Flag tagged IFT81, and patient and control fibroblasts were harvested and lysed in a RIPA buffer (Sigma Aldrich) containing complete protease inhibitor cocktail (Roche, Boulogne-Billancourt, France) on ice for 30 minutes with repeated mixing. Released DNA was fragmented by 20 seconds of Ultra-turrax homogenizer (Ika-Werke, Staufen, Germany) and the lysates were centrifuged (15,000g at 4 °C for 10 minutes). Proteins (50 µg) were denatured at 90 °C for 10 minutes in 4X premixed protein sample buffer (XT sample Buffer; Bio-Rad) and separated by electrophoresis (50 V for 30 minutes followed by 140 V for 90 minutes at room temperature) on Mini protean TGX 4-15% (Bio-Rad). Proteins were transferred (Trans-BlotR Bio-Rad) to PVDF membranes (Bio-Rad). Membranes were blocked with phosphate-buffered saline (PBS) 0.5% Tween-20/5% dry milk powder and incubated overnight at 4 °C under agitation with anti-IFT81, rabbit, polyclonal (Proteintech) 1:2000 dilutions. Membranes were washed three times in PBS 0.5% Tween-20 solution and incubated for 1 hour at room temperature with HRP-conjugated donkey anti-rabbit (Amersham GE Healthcare, Courtaboeuf, France) in 1:10,000 dilutions. ECL Western Blotting Detection Reagents (Amersham GE Healthcare) was applied according to the manufacturer's instructions and the blot was exposed to Chemi DocTM (Bio-Rad).
Figure S4. Ciliary staining of three additional IFT-B core components. Immuno-fluorescence staining was performed in cultured human fibroblasts from healthy controls and patient NCK033 (p.Asp672Alafs*15) after 48 hours of serum starvation. Note that ciliary localization of IFT88 (A), IFT46 (B), and RABL5/IFT22 (C) did not show significant difference between control and mutant fibroblasts.
Figure S5. Localization of Shh-pathway components in *IFT81* mutant fibroblasts (NCK033: p.Asp672Alafs*15) compared to human control fibroblasts. Immunofluorescence staining was performed in cultured human fibroblasts from healthy control and affected individual (p.Asp672Alafs*15) after 48 hours of serum starvation with or without smoothened agonist for 24 hours (SAG, 100nM, Santa Cruz). Cilia were stained using mouse monoclonal anti acetylated alpha tubulin, anti gamma tubulin, and either anti-SMO, anti-GLI1, or anti-GLI2 antibodies.

(A) Immunostaining show that SMO is evenly distributed under SAG activation both in the control and affected individual cells. (B) Immunostaining demonstrate unchanged localization of GLI1 with and without SAG in both cell lines. (C) Immunostaining evidence no ciliary localization change of GLI2 in the affected individual compared to the control cells. Scale bar represents 2mm.
Table S1. Fourteen genes, encoding IFT-B components, included in mutation analysis in 1,056 individuals with NPHP-RC at University of Michigan / Boston Children’s Hospital. B-Core proteins are highlighted in grey.

<table>
<thead>
<tr>
<th>No</th>
<th>Gene symbol</th>
<th>Gene name</th>
<th>Accession</th>
<th>Locus</th>
<th># Exons</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>IFT172/SLB</td>
<td>intraflagellar transport 172 homolog (Chlamydomonas)</td>
<td>NM_015662.1</td>
<td>chr2:27,667,241-27,712,571</td>
<td>48</td>
</tr>
<tr>
<td>2</td>
<td>IFT88</td>
<td>intraflagellar transport 88 homolog (Chlamydomonas)</td>
<td>NM_175605.3</td>
<td>chr13:21,141,208-21,265,576</td>
<td>26</td>
</tr>
<tr>
<td>3</td>
<td>IFT80</td>
<td>intraflagellar transport 80 homolog (Chlamydomonas)</td>
<td>NM_020800.2</td>
<td>chr3:159,976,255-160,102,434</td>
<td>19</td>
</tr>
<tr>
<td>4</td>
<td>IFT46</td>
<td>intraflagellar transport 46 homolog (Chlamydomonas)</td>
<td>NM_020153.3</td>
<td>chr11:118,415,243-118,436,791</td>
<td>11</td>
</tr>
<tr>
<td>5</td>
<td>IFT52</td>
<td>intraflagellar transport 52 homolog (Chlamydomonas)</td>
<td>NM_016004.2</td>
<td>chr20:42,219,579-42,275,861</td>
<td>14</td>
</tr>
<tr>
<td>6</td>
<td>IFT57/HIPPI</td>
<td>intraflagellar transport 57 homolog (Chlamydomonas)</td>
<td>NM_018010.3</td>
<td>chr3:107,879,659-107,941,417</td>
<td>11</td>
</tr>
<tr>
<td>7</td>
<td>IFT74/CCDC2</td>
<td>intraflagellar transport 74 homolog (Chlamydomonas)</td>
<td>NM_001099222.1</td>
<td>chr9:26,956,371-27,062,931</td>
<td>19</td>
</tr>
<tr>
<td>8</td>
<td>IFT81/CDV1</td>
<td>intraflagellar transport 81 homolog (Chlamydomonas)</td>
<td>NM_001143779.1</td>
<td>chr12:110,562,140-110,656,600</td>
<td>18</td>
</tr>
<tr>
<td>9</td>
<td>RABL5/IFT22</td>
<td>RAB, member RAS oncogene family-like 5 (Chlamydomonas)</td>
<td>NM_022777.2</td>
<td>chr7:100,956,648-100,965,093</td>
<td>5</td>
</tr>
<tr>
<td>10</td>
<td>TRAF3IP1/IFT54</td>
<td>TNF receptor-associated factor 3 interacting protein 1</td>
<td>NM_015650.3</td>
<td>chr2:239,229,185-239,309,541</td>
<td>17</td>
</tr>
<tr>
<td>11</td>
<td>HSPB11/IFT25</td>
<td>heat shock protein family B (small), member 11 (Chlamydomonas)</td>
<td>NM_016126.2</td>
<td>chr1:54,387,234-54,411,288</td>
<td>4</td>
</tr>
<tr>
<td>12</td>
<td>IFT20</td>
<td>intraflagellar transport 20 homolog (Chlamydomonas)</td>
<td>NM_174887.2</td>
<td>chr17:26,655,353-26,662,495</td>
<td>5</td>
</tr>
<tr>
<td>13</td>
<td>IFT27</td>
<td>intraflagellar transport 27 homolog (Chlamydomonas)</td>
<td>NM_001177701.2</td>
<td>chr22:37,154,246-37,172,172</td>
<td>7</td>
</tr>
<tr>
<td>14</td>
<td>TTC30B/IFT70</td>
<td>tetratricopeptide repeat domain 30B (Chlamydomonas)</td>
<td>NM_152517.2</td>
<td>chr2:178,414,886-178,417,524</td>
<td>1</td>
</tr>
</tbody>
</table>
Table S2. *GLI1*, *GLI2*, *SMO*, and *PTCH1* specific primers sequences for qRT-PCR.

<table>
<thead>
<tr>
<th>GENE</th>
<th>PRIMER SEQUENCE</th>
<th>ACCESSION #</th>
<th>LENGTH</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTCH1</td>
<td>F : GCTACTTACTCATGCTCGCC R : TCCGATCAATGAGCACAGGC</td>
<td>NM_001083605</td>
<td>140</td>
</tr>
<tr>
<td>SMO</td>
<td>F : GGGAGGCTACTCTTCTCATCC R : TGGTCTCGTTGATCTTCTTG</td>
<td>NM_005631</td>
<td>103</td>
</tr>
<tr>
<td>GLI1</td>
<td>F : AGAGGGTGCCATGAAGCCAC R : AAGGTCCCTCGTCCAAGCTG</td>
<td>NM_005269.2</td>
<td>161</td>
</tr>
<tr>
<td>GLI2</td>
<td>F : TGACACCAACCAGAACAAGC R : GTCCAGACACCTGGCCCTG</td>
<td>NM_005270</td>
<td>156</td>
</tr>
</tbody>
</table>